Home > News > 67/Eligibility for the subcutaneous implantable cardiac defibrillator therapy using standard screening practice – our experience
Devices
Read Time: 2 mins

67/Eligibility for the subcutaneous implantable cardiac defibrillator therapy using standard screening practice – our experience

Published Online: October 3rd 2021 European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr67
Authors: M El Refai (Presenting Author) - University Hospital of Southampton, Southampton; M Abouel Asaad - University Hospital of Southampton, Southampton; VT - University Hospital of Southampton, Southampton; C Menexi - University Hospital of Southampton, Southampton; PR Roberts - University Hospital of Southampton, Southampton
Quick Links:
Article
Article Information
Article:

Introduction: Subcutaneous ICD (S-ICD) was designed to avoid complications associated with transvenous ICDs. But not all patients are eligible for S-ICDs and eligibility is identified after screening S-ICD candidates using guidelines by the device manufacturer. The S-ICD is particularly valuable for younger patients such as congenital heart disease (CHD) and hypertrophic cardiomyopathy (HCM) patients requiring longer defibrillation protection, but information regarding suitability for S-ICD in these populations is scarce with few studies reporting ineligibility rates between 24.6-56 % and between 7-38% for the CHD and HCM patients, respectively. These rates may be due to abnormal T-wave morphology resulting from structural changes that characterizes these patients’ groups. We report our experience with S-ICD screening in real-world population as a tertiary referral centre for complex cardiac devices in the UK.

Methodology: We performed a retrograde analysis on patients with an indication for an ICD who had screening for S-ICD eligibility at our centre between 2014 and 2021. Patients were considered eligible if they had at least one vector that passed the screening in two postures as recommended by the device manufacturer.

Results: A total of 189 (Mean age 47.2 years, 64.6% males) patients were included. Mean BMI was 27.9. Underlying heart conditions were dilated cardiomyopathy 47 (24.9%), structurally normal heart 46 (24.3%), HCM 37 (19.6%), ischaemic cardiomyopathy 36 (19%), CHD 19 (10.1%) and arrhythmogenic right ventricular cardiomyopathy 4 (2.1%). 182 (96.3%) patients met the eligibility criteria for an S-ICD. There was no statistically significant difference in the S-ICD eligibility based on age, sex, or BMI or between patients with different underlying heart conditions (Figure 1).

Conclusions: Our analysis showed that most of the patients- regardless of underlying cardiac condition- are likely to be deemed S-ICD eligible following current screening practices.

Article Information:

Further Resources

Share this Article
Related Content In Devices
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72